Clinical Trial Update: Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating gefitinib as maintenance therapy in locally advanced or metastatic non-small cell lung cancer completed, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (Gefitinib) (Gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 4 | Status: COMPLETED | Results posted: 2012-08-20